Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Geron Corp (GERN)

Geron Corp (GERN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,063,305
  • Shares Outstanding, K 640,545
  • Annual Sales, $ 183,880 K
  • Annual Income, $ -83,500 K
  • EBIT $ -52 M
  • EBITDA $ -56 M
  • 60-Month Beta 0.67
  • Price/Sales 5.19
  • Price/Cash Flow N/A
  • Price/Book 4.21

Options Overview Details

View History
  • Implied Volatility 112.84% (-2.31%)
  • Historical Volatility 87.83%
  • IV Percentile 34%
  • IV Rank 13.06%
  • IV High 429.98% on 10/10/25
  • IV Low 65.22% on 06/04/25
  • Expected Move (DTE 15) 0.2125 (12.60%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 235
  • Volume Avg (30-Day) 890
  • Put/Call OI Ratio 0.46
  • Today's Open Interest 54,602
  • Open Int (30-Day) 63,538
  • Expected Range 1.4741 to 1.8991

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.03
  • Number of Estimates 4
  • High Estimate $-0.02
  • Low Estimate $-0.03
  • Prior Year $-0.03
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3800 +22.10%
on 03/30/26
1.7200 -2.03%
on 03/16/26
+0.1350 (+8.71%)
since 03/02/26
3-Month
1.2600 +33.73%
on 01/20/26
2.0100 -16.17%
on 02/19/26
+0.3650 (+27.65%)
since 01/02/26
52-Week
1.0400 +62.02%
on 11/07/25
2.0100 -16.17%
on 02/19/26
+0.0950 (+5.97%)
since 04/02/25

Most Recent Stories

More News
Geron Announces Appointment of New Members to its Board of Directors

FOSTER CITY, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...

GERN : 1.6650 (+0.30%)
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective March 17, 2026, it granted stock...

GERN : 1.6650 (+0.30%)
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:NTLA),(NASDAQ:NAGE),(NASDAQ:OCGN) EQNX::TICKER_END

AVAI : 0.2875 (-4.17%)
NAGE : 4.39 (-2.88%)
GERN : 1.6650 (+0.30%)
NTLA : 12.95 (-2.41%)
OCGN : 1.7600 (-1.68%)
Geron: Q4 Earnings Snapshot

Geron: Q4 Earnings Snapshot

GERN : 1.6650 (+0.30%)
Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Achieved $48 million and $184 million in RYTELO ® (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025,...

GERN : 1.6650 (+0.30%)
Geron Plans to Present at Upcoming Investor Conferences

FOSTER CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...

GERN : 1.6650 (+0.30%)
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective February 17, 2026, it granted stock...

GERN : 1.6650 (+0.30%)
Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

FOSTER CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today...

GERN : 1.6650 (+0.30%)
Geron Corporation Provides 2026 Financial Guidance

2026 RYTELO ® (imetelstat) net product revenue expected in the range of $220 to $240 million 2026 total operating expenses expected in the range of $230 to $240 million Expected top-line...

GERN : 1.6650 (+0.30%)
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective December 17, 2025, it granted stock...

GERN : 1.6650 (+0.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic...

See More

Key Turning Points

3rd Resistance Point 1.8733
2nd Resistance Point 1.7667
1st Resistance Point 1.7133
Last Price 1.6650
1st Support Level 1.5533
2nd Support Level 1.4467
3rd Support Level 1.3933

See More

52-Week High 2.0100
Last Price 1.6650
Fibonacci 61.8% 1.6395
Fibonacci 50% 1.5250
Fibonacci 38.2% 1.4105
52-Week Low 1.0400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.